Chronic myeloid leukemia (CML): prognostic factors and survival analysis.
The prognostic value of different factors upon diagnosis of CML was analysed in 45 Philadelphia (Ph1)-positive patients. The median survival was 48 months. Univariate analysis showed 5 poor prognostic factors (male sex, under 45 years-old, bone marrow blasts greater than or equal to 10 percent, blood basophils greater than or equal to 6 percent and blood eosinophils greater than or equal to 6 percent) which provided for the development of a clinical staging system: Stage I with none or one factor and a two-year survival rate of 100 percent; Stage II with two or three factors and two-year survival of 72.2 percent; and Stage III with four or five factors and two-year survival of 0 percent (p = 0.00016). Multivariate survival analysis showed that combination of blood basophilia and bone marrow blasts had the strongest predictive relationship to survival time. We conclude that a combination of pretreatment factors identifies different risk subcategories in CML patients and is helpful in assessing the overall prognosis and the treatment approach.
Braga
G W
GW
Disciplina de Hematologia e Hemoterapia, Universidade Federal de São Paulo, Brazil.
Chauffaille
M L
ML
Moncau
J E
JE
Souto
E X
EX
Silva
M R
MR
Kerbauy
J
J
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D001491:Basophils; D001752:Blast Crisis; D001853:Bone Marrow; D002908:Chronic Disease; D004804:Eosinophils; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000453:epidemiology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011379:Prognosis; D012306:Risk; D012737:Sex Factors; D016019:Survival Analysis